Where to Buy Tribulus to Correct Low Female Sexual Desire
Low Female Sexual Desire
Low female sexual desire is a widespread problem.
Expert Available For Menopause Awareness Month To Discuss New
Advances For Treating Female Sexual Dysfunction
09 Aug 2008
This August is Menopause Awareness Month, a good time for
women to discuss with their
doctors female sexual dysfunction, a real but
often-overlooked medical condition. It may be
surprising to learn that approximately
forty million American women suffer from some type
of female sexual dysfunction (FSD),
which can arise from many causes, including increasing
age, certain surgical
procedures, the use of prescription pharmaceuticals, disease, or
chemical
imbalances.
The most common form of FSD is Hypoactive Sexual Desire
Disorder (HSDD), sometimes
referred to as low sex drive. In a study
published in the July 14, 2008 edition of the
prestigious medical journal, Archives of
Internal Medicine, researchers found that
the prevalence of low sexual
desire ranged from 26.7% among pre-menopausal
women, to 52% among
post- menopausal women. Moreover, the incidence of HSDD
was as
high as 12.5% in surgically menopausal women. (This group of women has had
their
ovaries removed.)
HSDD has been treated with testosterone for many years,
although the hormone has not
been specifically approved for that use to date.
Although testosterone is popularly thought
of as a male hormone, it also is found in
women. Researchers believe, and recent clinical
trials support that testosterone
levels, which fall with increasing age or the removal of the
ovaries, may influence a
woman's sexual desire.
One treatment option in development, LibiGel® by BioSante
Pharmaceuticals, Inc.
(Nasdaq: BPAX) is designed to restore testosterone levels in
post-menopausal women to
levels that are considered normal to maintain a
healthy libido. LibiGel® is applied once daily
using a metered dose bottle that
administers a pea-sized amount of gel to be rubbed into the
upper arm, delivering the
required therapy to the bloodstream evenly over twenty-four
hours. The gel is
quick drying, non- invasive, and painless leaving no trace of residue with
virtually no site irritation.
After nearly a decade of research and development and tests
involving three thousand
women, Pfizer, creators of the blockbuster male
erectile dysfunction
drug, Viagra,
discontinued its own attempt at a female sexual
dysfunction drug in February 2004
following clinical trial failures. According to
a February 28, 2004 article in the New York
Times, while Pfizer's drug, a
compound named R-13, was able to create "the outward signs
of arousal in many women,
that seems to have little effect on a woman's willingness, or
desire, to have
sex." By comparison, in a Phase II clinical trial, LibiGel® increased the
number of
satisfying "sexual events" by 238%.
Currently undergoing Phase III testing, LibiGel® likely will
become the first FDA approved
treatment specifically indicated for HSDD in
menopausal women, if safety and efficacy
endpoints are met and the FDA approves
the drug.
For those covering this news, BioSante Pharmaceuticals makes
available Dr. Sheryl A.
Kingsberg, clinical psychologist and associate
professor in the Departments of
Reproductive Biology and Psychiatry at Case
Western Reserve University School of
Medicine.
Topics for discussion include:
-- How might physicians better initiate discussions about
female sexual dysfunction with
post-menopausal patients?
-- What are some of the causes of female sexual dysfunction
in post-menopausal women?
-- What are some of the negative effects of a sudden drop in
female sexual desire?
-- How does testosterone, popularly thought of as a male
hormone, influence female sexual
desire?
-- Why did Pfizer abandon its decade-long attempt at a female
sexual dysfunction drug?
-- How does BioSante's LibiGel ® address Hypoactive Sexual
Desire Disorder and when
might it be available to post-menopausal patients?
About Sheryl A. Kingsberg, PhD
Dr. Kingsberg is a clinical psychologist and associate
professor in the Departments of
Reproductive Biology and Psychiatry at Case Western
Reserve University School of
Medicine. She is also the chief of the Division of
Behavioral Medicine in the Department of
Obstetrics/Gynecology at MacDonald Women's
Hospital.
Dr. Kingsberg has authored numerous peer-reviewed manuscripts
as well as several book
chapters on topics including menopause and
sexuality, sexual a version disorder, the
treatment of psychogenic erectile
dysfunction, oocyte donation, and infertility. She sits on
the editorial boards
for the journals Menopause and the International Journal of Impotence
Research. Her main
research interests are in sexual medicine and the psychological aspects
of
infertility and menopause.
Dr. Kingsberg discloses that she has received funding from
BioSante, Boehringer Ingelheim,
Eli Lilly, and Procter and Gamble.
About BioSante Pharmaceuticals, Inc. (Nasdaq: BPAX)
BioSante is a specialty pharmaceutical company focused on
developing products for female
sexual health, menopause, contraception and male hypogonadism. BioSante's lead products
include LibiGel® (transdermal
testosterone gel) in Phase III clinical development by
BioSante under a U.S. Food and
Drug Administration (FDA) SPA (Special Protocol
Assessment) for the treatment of
female sexual dysfunction (FSD), and Elestrin™ (estradiol
gel) developed
through FDA approval by BioSante, indicated for the treatment of
moderate-to-severe vasomotor symptoms associated with menopause, currently
marketed
in the U.S. Also in development are Bio-T-Gel™, a testosterone gel for
male
hypogonadism, and an oral contraceptive in Phase II clinical development
using BioSante
patented technology. The current market in the U.S. for estrogen and
testosterone products
is approximately $2.5 billion and for oral contraceptives
approximately $3 billion. The
company also is developing its calcium phosphate
technology (CaP) for novel vaccines,
drug delivery and aesthetic medicine (BioLook™).
Additional information is available online
at:
http://www.biosantepharma.com.
BioSante Pharmaceuticals http://www.biosantepharma.com
|
